BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 549 filers reported holding BIO-TECHNE CORP in Q1 2022. The put-call ratio across all filers is 0.27 and the average weighting 0.2%.
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ownership Capital B.V. | 840,131 | $363,810,000 | 4.80% |
| Montanaro Asset Management Ltd | 89,950 | $38,952,000 | 4.80% |
| Sandhill Capital Partners LLC | 109,939 | $47,608,000 | 4.09% |
| Brown Capital Management | 918,328 | $397,673,000 | 3.96% |
| STONE RUN CAPITAL, LLC | 22,325 | $9,668,000 | 3.57% |
| DF DENT & CO INC | 686,484 | $297,275,000 | 3.42% |
| Westwind Capital | 27,741 | $12,013,000 | 3.23% |
| MAIRS & POWER INC | 657,962 | $284,924,000 | 2.87% |
| Summit Creek Advisors LLC | 58,133 | $25,174,000 | 2.85% |
| Pembroke Management, LTD | 76,250 | $33,019,000 | 2.76% |
| Aristotle Atlantic Partners, LLC | 97,025 | $42,016,000 | 2.60% |
| OBERMEYER WOOD INVESTMENT COUNSEL, LLLP | 100,204 | $43,392,000 | 2.60% |
| Jackson Square Partners, LLC | 580,743 | $251,484,000 | 2.50% |
| AMERICAN CAPITAL MANAGEMENT INC | 192,773 | $83,478,000 | 2.46% |
| GENEVA CAPITAL MANAGEMENT LLC | 257,652 | $111,574,000 | 2.16% |
| CROWN ADVISORS MANAGEMENT, INC. | 6,000 | $2,598,000 | 1.83% |
| BAMCO INC /NY/ | 1,469,118 | $636,187,000 | 1.56% |
| Winslow Capital Management, LLC | 734,215 | $317,944,000 | 1.38% |
| Affiance Financial, LLC | 6,258 | $2,710,000 | 1.32% |
| ROWLANDMILLER & PARTNERS.ADV | 13,070 | $5,659,832,000 | 1.31% |
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
External links
This page lists BIO-TECHNE CORP's shareholders in Q1 2022. To view BIO-TECHNE CORP's shareholder history, click here.